Table 3 Summary of AEs in patients with LMD from any solid tumor
Types of AEs, n (%) | n = 22 |
|---|---|
AEs | 21 (95.5%) |
TEAEs | 21 (95.5%) |
HER3-DXd-related TEAEs | 18 (81.8%) |
Serious TEAEs | 11 (50.0%) |
Serious HER3-DXd-related TEAEs | 4 (18.2%) |
Grade 3–5 TEAEs | 15 (68.2%) |
Grade 3–5 HER3-DXd-related TEAEs | 7 (31.8%) |
AESIs | 1 (4.5%) |
HER3-DXd-related AESIs | 1 (4.5%) |
Death due to TEAEs | 0 (0.0%) |
Death due to HER3-DXd-related TEAEs | 0 (0.0%) |
TEAEs leading to dose reduction | 2 (9.1%) |
TEAEs leading to dose interruption | 6 (27.3%) |
TEAEs leading to permanent discontinuation | 1 (4.5%) |
